XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
XCSport体育:Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
Innovation Centre
XCSport体育:Technology Platform
XCSport体育:Quality Management
Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
XCSport体育:Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
XCSport体育:Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
XCSport体育:Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
XCSport体育:Marketed Products
Products in R&D
XCSport体育:Clinical Trial
XCSport体育:Science & Technology
XCSport体育:R&D Result
XCSport体育:Innovation Centre
Technology Platform
Quality Management
Manufacturing
XCSport体育:Collaborations
XCSport体育:Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
XCSport体育:Talent Philosophy
Staff Life
Training and Development
Job Opportunities
XCSport体育:Contact Us
Contact Information
Customer Message
Privacy
XCSport体育:Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Popular Science
Highlights
Download
Media Reports
XCSport体育:Media Enquiry
2019-11-29
ruizhen.netpleted Data Analysis of the Phase 1 Study for Its HLX03
2019-11-26
Henlius HLX22 Received IND Application Acceptance Notification from NMPA
2019-11-16
Henlius Successfully Held Its Second Scientific Advisory Board (SAB) Meeting in California
2019-11-01
Cooperation Upgrades! Henlius Has been Granted to Develop and Commercialize AC101 in the World
2019-10-26
New Progress! Henlius Received Clinical Approval for Its Anti-VEGFR2 Monoclonal Antibody, HLX12
2019-10-18
Henlius Nominated for the Global Generics & Biosimilars Awards 2018 in Two Categories
2019-09-10
Important News! ruizhen.netbination Therapy Received Approval to Conduct Clinical Trials in China
2019-08-09
Henlius Submitted Investigational New Drug Application for Its HLX12
2019-06-21
Henlius and Accord Entered into an License Agreement for HLX02
1
2